Gut bugs may predict lymphoma drug success
NCT ID NCT07498920
First seen Mar 31, 2026 · Last updated May 08, 2026 · Updated 8 times
Summary
This study looks at how the bacteria in your gut might influence how well a drug called glofitamab works against a type of lymphoma (DLBCL). Researchers will collect stool samples from 30 patients before, during, and up to one year after treatment to see if certain gut bacteria are linked to better outcomes or fewer side effects. The goal is to learn, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.